BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

NCT01121393 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

364

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung
Adenocarcinoma

Interventions

DRUG: Gemcitabine+Cisplatin
DRUG: BIBW 2992

Sponsor

Boehringer Ingelheim